<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="block">
            <roleset id="block.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="causer agent&#x0A;" />
                    <role n="1" descr="theme (process or entity being stopped)&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation might be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation were able to be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation were believed to be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation would be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine could block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine had blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine might block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine might have blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine was able to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine was believed to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine was believed to have blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine was blocking agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling because of staurosporines ability to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling because of staurosporines blocking agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation are able to be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation are believed to be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation are blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation can be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation have been blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation may be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation were blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation will be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine can block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine has blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine is able to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine is believed to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine is believed to have blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine is blocking agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine may block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine may have blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Alanine blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Alanine blocks the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Alanine can block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Alanine can have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Alanine could block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Alanine could have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Alanine has blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Alanine is able to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Alanine is believed to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Alanine may block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Alanine may have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Alanine might block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>Alanine might have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>Alanine was able to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Alanine was believed to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Alanine will block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Alanine would block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 are shown to be able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 are shown to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 are shown to have blocked merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 have been shown to be able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 have been shown to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 have been shown to have blocked merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 blocked merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 can block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 may block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 were able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro can be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro could be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro has been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro is believed to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro is blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro may be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro might be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro was believed to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro will be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro would be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>Both RAP1 and 2 are important vaccine candidates because merozoite invasion in vitro is shown to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>Both RAP1 and 2 are important vaccine candidates because merozoite invasion in vitro is shown to have been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>Both RAP1 and 2 are important vaccine candidates because merozoite invasion in vitro was shown to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>Both RAP1 and 2 are important vaccine candidates because merozoite invasion in vitro was shown to have been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>It blocked membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>It blocks membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>It can block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>It could block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>It has blocked membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>It is able to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>It is believed to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>It may block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>It might block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>It was able to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>It was believed to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>It will block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>It would block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since labeling can be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since labeling is able to be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since labeling is believed to be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide blocks labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide can block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide can have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide is able to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide may block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide may have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide will block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling could be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling has been blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling was able to be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling was believed to be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling was blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide could block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide could have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide might block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide might have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide was able to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide would block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide would have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Membranes are able to be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Membranes are believed to be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Membranes are blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Membranes can be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Membranes has been blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Membranes may be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Membranes will be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Mutations at the 3 splice site being able to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Mutations at the 3 splice site believed to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>Mutations at the 3 splice site specifically blocking step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>Mutations at the 3 splice site that are able to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>Mutations at the 3 splice site that are believed to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>Mutations at the 3 splice site that are shown to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>Mutations at the 3 splice site that can specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>Mutations at the 3 splice site that have specifically blocked step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>Mutations at the 3 splice site that may specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>Mutations at the 3 splice site that specifically blocked step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation blocks myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation can block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is believed to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is believed to have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is proven to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is proven to have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation can be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation is believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation is blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation may be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation will be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation has been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation was blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation can not block elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation is not able to block elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and elevation of GR by 14-3-3eta can not be blocked by inhibition of translation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and elevation of GR by 14-3-3eta is believed not to be blocked by inhibition of translation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and elevation of GR by 14-3-3eta is not able to be blocked by inhibition of translation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and elevation of GR by 14-3-3eta is not blocked by inhibition of translation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation does not block elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation has not blocked elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation will not block elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Step II can be specifically blocked by mutations at the 3 splice site which do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Step II is believed to be specifically blocked by mutations at the 3 splice site which do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Step II is specifically blocked by mutations at the 3 splice site which do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Step II was specifically blocked by mutations at the 3 splice site which do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because RNA polymerase during elongation can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because RNA polymerase during elongation is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because RNA polymerase during elongation is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because RNA polymerase during elongation was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because it blocked RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because it can block RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because it is able to block RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because it may blocks RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway blocking the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway by blocking the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway for blocking the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway that blocked the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway that have blocked the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>the action of a postulated repressor can be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>the action of a postulated repressor has been blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>the action of a postulated repressor is blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>the action of a postulated repressor was blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
